| Literature DB >> 35592283 |
Gaber E El-Desoky1, Saikh M Wabaidur1, Zeid A AlOthman1, Mohamed A Habila1.
Abstract
In the current study, 40 albino male rats were investigated to evaluate the impact of Nano-curcumin (Nano-CUR) administration against Tartrazine (TZ)-induced variations in kidney and liver histology and their related functions. The liver function biomarkers are (glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transaminase (GGT), alkaline phosphatase (ALP), total bilirubin (T. BiLL)), whereas the kidney biomarkers are (creatinine, uric acid, urea, globulin, total protein (TP)), as well as blood parameters of (serum glucose (sGlu), alpha-fetoprotein (AFP), protein Kinase-C (PKC)) and lipid profiles that include (total lipids (TL), triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density L-C (HDL-C), and very-low-density L-C (VLDL-C)). The collected rats were randomly separated into four different groups (G1, G2, G3, and G4) of 10 rats each, where G1 stands for control, G2 for TZ-ingestion, G3 for Nano-CUR-ingestion, and G4 for (TZ + Nano-CUR mix.) ingestion. TZ-ingestion significantly (p < .05) increases the liver function enzymes' activity, total bilirubin and kidney biomarkers (creatinine, urea, uric acid, total protein (TP), globulin (Glu)). Also, TZ-ingestion significantly increased sGlu, PKC, AFP, as well as lipid profiles, while there were significant (p < .05) decreases in HDL-C and albumin (Alb) concentrations compared to control. Histopathological changes in liver, such as dilatation of blood sinusoids and central vein with hemorrhage and necrosis, were observed due to TZ-ingestion. Similarly, TZ-ingestion influenced kidney tissues in terms of tubular dilatation with tubular degeneration, thickened basement membrane, and dilatation of the glomerular capillaries. Markedly, the administration of Nano-CUR significantly decreased liver and kidney function enzymes as well as sGlu, AFP, and PKC, whereas it significantly increased serum Alb and HDL-C levels compared to control and TZ-ingested rats. All values arranged around normal control values. Also, the liver tissue of Nano-CUR-ingested rats showed a normal arrangement of normal blood sinusoids(s), hepatic cords, and hepatocytes as compared to controls. The same results were also found in the section of rat kidney ingested with 2.00 g of Nano-CUR/(kg B.W.) showing near-normal architecture as compared to control rats. The liver tissue of rats ingested by a mixture of (7.5 mg of TZ + 2.0 g of Nano-CUR/kg B.W.) showed little necrosis. Similarly, a section of rat kidney ingested a mixture of (7.5 mg of TZ + 2.00 g of Nano-CUR/kg B.W.) which revealed mild tubular degeneration and dilatation of the glomerular capillaries. These results support the protective and therapeutic effects of Nano-CUR on the histology of liver and kidneys and their related function biomarkers. Also, Nano-CUR corrects the imbalance in serum glucose (sGlu), AFP, PKC, and lipid profiles in TZ-ingested rats compared to control.Entities:
Keywords: curcumin; experimental rats; nanomaterials; tartrazine; therapeutic effects
Year: 2022 PMID: 35592283 PMCID: PMC9094471 DOI: 10.1002/fsn3.2790
Source DB: PubMed Journal: Food Sci Nutr ISSN: 2048-7177 Impact factor: 3.553
FIGURE 1Chemical structure of Tartrazine
Effect of Tartrazine (TZ) and Nano‐curcumin (Nano‐CUR) on different parts in male albino rats
|
Groups→ Parameters↓ | Control | TZ | Nano‐CUR | TZ + Nano‐CUR |
|---|---|---|---|---|
| Initial B.W. | 198.3 ± 3.21 | 201.1 ± 4.11 | 196.3 ± 2.31 | 199.6 ± 3.14 |
| Final B.W. | 224.1 ± 6.10 | 189.2 ± 4.33** | 223.6 ± 5.22 | 225.6 ± 2.11 |
| Weight gain | 25.8 ± 1.51 | −11.9 ± 0.21** | 27.3 ± 1.52 | 26.0 ± 1.21 |
| Liver weight | 5.10 ± 0.001 | 5.30 ± 0.021** | 5.00 ± 0.050 | 5.20 ± 0.031 |
|
Relative liver weight | 0.0227 ± 0.0005 | 0.0281 ± 0.0001** | 0.0224 ± 0.0005 | 0.0230 ± 0.0004 |
| Kidney weight | 1.56 ± 0.01 | 1.61 ± 0.3** | 1.54 ± 0.07 | 1.58 ± 0.009 |
|
Relative kidney weight | 0.0069 ± 0.0001 | 0.0085±**0.0001 | 0.0068 ± 0.0009 | 0.0070 ± 0.0005 |
Each value is the mean ± SD, n = 8. Values marked with ** differ significantly from control value: p < .05.
Effect of Tartrazine (TZ) and Nano‐curcumin (Nano‐CUR) on liver functions (enzymes and total bilirubin) in male albino rats
|
Groups→ Parameters↓ | Control | TZ | Nano‐CUR | TZ +Nano‐CUR |
|---|---|---|---|---|
| AST (U/L) | 48.57 ± 1.75 | 97.32 ± 7.82** | 47.83 ± 2.81 | 49.22 ± 3.60 |
| ALT (U/L) | 11.57 ± 1.75 | 35.51 ± 3.56** | 10.12 ± 1.96 | 12.70 ± 1.90 |
| GGT(IU/L) | 5.96 ± 2.23 | 18.54 ± 3.20** | 6.74 ± 2.1 | 7.53 ± 1.70 |
| ALP (U/L) | 89.62 ± 3.26 | 147.83 ± 9.65** | 91.25 ± 6.81 | 93.10 ± 9.17 |
| T. BiLL (mg/dl) | 1.2 ± 0.14 | 1.9 ± 0,15** | 1.3 ± 0.21 | 1.4 ± 0.22 |
Each value is the mean ± SE, n = 8. Values marked with ** differ significantly from control value: p < .01.
Effect of Tartrazine (TZ) and Nano‐curcumin (Nano‐CUR) on serum blood glucose (sGlu), protein Kinase‐C (PKC), and alpha‐fetoprotein (AFP) in adult male albino rats
|
Groups→ Parameters↓ |
Control G1 |
TZ G2 |
Nano‐CUR G3 |
TZ + Nano‐CUR G4 |
|---|---|---|---|---|
| sGlu, mg/dl | 169.8 ± 4.23 | 196.66 ± 4.66** | 170.16 ± 3.86 | 171.87 ± 3.78 |
| PKC, Pmol/L | 0.96 ± 0.31 | 3.98 ± 0.42** | 0.95 ± 0.51 | 4.43 ± 0.61 |
| AFP, ng/ml | 25.27 ± 1.33 | 102.51 ± 3.53** | 24.87 ± 2.11 | 26.56 ± 3.12 |
Each value is the mean ± SD, n = 8. Values marked with ** differ significantly from control value: p < .01.
Effect of Tartrazine (TZ) and Nano‐curcumin (Nano‐CUR) on kidney functions (urea, creatinine, uric acid, total protein (TP), albumin (Alb), globulin (Glu), and Alb/Glu ratio) in male albino rats
|
Groups→ Parameters↓ | Control | TZ | Nano‐CUR | TZ + Nano‐CUR |
|---|---|---|---|---|
| Urea | 44.41 ± 1.61 | 156.69 ± 6.42** | 45.12 ± 1.35 | 47.13 ± 1.22 |
| Creatinine | 0.51 ± 0.02 | 1.02 ± 0.07** | 0.49 ± 0.04 | 0.53 ± 0.07 |
| Uric acid | 0.43 ± 0.03 | 1.7 ± 0.06** | 0.41 ± 0.5 | 0.51 ± 0.08 |
| TP (g/dl) | 7.62 ± 0.47 | 8.74 ± 0.83** | 7.50 ± 0.43 | 7.53 ± 1.43 |
| Alb. (g/dl) | 4.11 ± 1.04 | 5.40 ± 1.25* | 4.40 ± 2.11 | 4.46 ± 0.84 |
| Glob. (g/dl) | 2.90 ± 2.31 | 3.13 ± 0.21** | 3.01 ± 3.12 | 3.00 ± 0.99 |
| Alb/Glob. ratio | 1.42 ± 1.67 | 1.73 ± 0.77** | 1.50 ± 2.66 | 1.51 ± 0.92 |
Each value is the mean ± SE, n = 8. Values marked with ** differ significantly from control value: p < .01.
Effect of Tartrazine (TZ) and Nano‐curcumin (Nano‐CUR) on serum lipid profile in rats
|
Groups→ Parameters↓ | Control | TZ | Nano‐CUR | TZ +Nano‐CUR |
|---|---|---|---|---|
| TL (mg/dL) | 139.33 ± 2.48 | 359.39 ± 5.66** | 143.42 ± 32 | 151.46 ± 53 |
| TG (mg/dL) | 61.15 ± 2.35 | 103.81 ± 6.26** | 65.36 ± 2.50 | 66.76 ± 4.43 |
| TC (mg/dL) | 70.68 ± 1.25 | 99.52 ± 10.41** | 66.73 ± 3.93 | 71.66 ± 5.16 |
| HDL‐C (mg/dL) | 34.90 ± 2.01 | 25.69 ± 2.32** | 35.23 ± 3.18 | 33.18 ± 3.60 |
| LDL‐C (mg/dL) | 25.39 ± 2.65 | 62.75 ± 5.92** | 22.82 ± 2.11 | 26.11 ± 4.63 |
| VLDL‐C (mg/dL) | 10.51 ± 2.21 | 12.34 ± 1.36* | 10.73 ± 2.23 | 11.15 ± 2.27 |
Each value is the mean ± SE, n = 8. Values marked with ** differ significantly from control value: p < .01, those marked with *differ significantly from control group: p < .05.
FIGURE 2Histopathology of livers of rats ingested Tartrazine (TZ) and the ameliorative effects of Nano‐curcumin (Nano‐CUR). (a) Normal structure of the liver tissue of G1 displaying the normal arrangement of hepatic cords, central vein, normal blood sinusoids(s), and hepatocytes, HE, ×400; (b) Liver tissue of rats ingested 7.5 mg of TZ/kg B.W., displaying dilatation of blood sinusoids and central vein with necrosis and hemorrhage (*), HE, ×400; (c) Liver tissue of rats ingested 2.0 g of Nano‐CUR/kg B.W., displaying a normal arrangement of normal blood sinusoids(s), hepatocytes, and hepatic cords as compared to the controls, HE, ×400; (d) Liver tissue of rats ingested 7.5 mg of TZ + 2.0 g of Nano‐CUR/kg B.W., showing little necrosis (N), hematoxylin and eosin (H&E), ×400
FIGURE 3Histopathology of kidneys of rats ingested Tartrazine (TZ) and the ameliorative effects of Nano‐curcumin (Nano‐CUR). (a): Sectional part of G1 rats displays a normal histological appearance of the kidney. (b): Section of the rat kidney treated with 7.5 mg of TZ/(kg B.W.) discovered tubular dilatation with tubular degeneration, thickened basement membrane, and the glomerular capillaries’ dilatation (black arrow). (c): Section of the rat kidney ingested 2.00 g of Nano‐CUR/(kg B.W.) showed near‐normal architecture as compared to control rats. (d): Section of rat kidney ingested a mix. of (7.5 mg of TZ + 2.00 g of Nano‐CUR per kg B.W.) showed slight tubular degeneration and the glomerular capillaries’ dilatation (black arrow)